Seeking Alpha

Oppenheimer assumes ViroPharma (VPHM) at Outperform with a $35 price target citing an improved...

Oppenheimer assumes ViroPharma (VPHM) at Outperform with a $35 price target citing an improved outlook for H2 2013-2014 characterized by "continued Cinryze growth (lapping the comps on Vancocin) and continued news flow from the pipeline." Analyst Akiva Felt also calls Maribavir development a "call option with near-term catalyst potential.” (Previous: VPHM spikes on buyout chatter)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs